TP53 and small cell lung carcinoma: A subsequent randomized phase II trial enrolled 69 patients with ES-SCLC who had completed 4–6 cycles of initial platinum plus etoposide chemotherapy to receive observation, the Ad.p53 DC vaccine, or vaccine plus all-trans-retinoic acid (ATRA) (48).